Johnson & Johnson vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027?
Johnson & Johnson's diversified MedTech and pharma mix faces off against Vertex's cystic fibrosis dominance, but their valuation gap tells a story worth weighing.
\